X
23Jul

CTS conversion to the Ortho VERSEIA Integrated Processor (VIP) in January 2021

0 Comments | | Return |

After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.

Read all about it on the Communication page by clicking this link: Communications

Related

Exhibiting at AABB Annual Meeting- Booth 732

We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...

Read More >

CTS Implements HLA Class I and II Testing on the Gemini

CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...

Read More >

Reminder- Health and Human Services (HHS) email notifications for WNV reactives

Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...

Read More >

CTS implements Ultrio Plus on the Panther

In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...

Read More >

Reminder- Check flights and cargo hours for the Memorial Day Holiday

As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...

Read More >

FDA Releases ZIKV Guidance and Grifols ZIKV Assay Licensed- 1st Update

This is the first update to the original CTS communication distributed on July 6th. As previously co...

Read More >

Subscribe here to receive CTS updates!

Name